Paul Tudor Jones's KROS Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 28,007 shares of Keros Therapeutics, Inc. (KROS) worth $309,197, representing 0.00% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in KROS, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 19,525 shares. Largest reduction occurred in Q2 2025, reducing 19,858 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Keros Therapeutics (KROS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Keros Therapeutics (KROS) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -300 | Reduce 1.06% | 28,007 | $11.04 |
| Q4 2025 | +8,782 | Add 44.98% | 28,307 | $20.36 |
| Q3 2025 | +19,525 | New Buy | 19,525 | $15.82 |
| Q2 2025 | -19,858 | Sold Out | 0 | $0.00 |
| Q1 2025 | +4,527 | Add 29.53% | 19,858 | $10.19 |
| Q4 2024 | -4,456 | Reduce 22.52% | 15,331 | $15.83 |
| Q3 2024 | +9,430 | Add 91.05% | 19,787 | $58.07 |
| Q2 2024 | -6,646 | Reduce 39.09% | 10,357 | $45.70 |
| Q1 2024 | +7,560 | Add 80.06% | 17,003 | $66.20 |
| Q4 2023 | +9,443 | New Buy | 9,443 | $39.76 |
| Q2 2023 | -17,666 | Sold Out | 0 | $0.00 |
| Q1 2023 | +17,666 | New Buy | 17,666 | $0.04 |
| Q4 2022 | -12,829 | Sold Out | 0 | $0.00 |
| Q3 2022 | +636 | Add 5.22% | 12,829 | $37.65 |
| Q2 2022 | +12,193 | New Buy | 12,193 | $27.64 |
Paul Tudor Jones's Keros Therapeutics Investment FAQs
Paul Tudor Jones first purchased Keros Therapeutics, Inc. (KROS) in Q2 2022, acquiring 12,193 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Keros Therapeutics, Inc. (KROS) for 15 quarters since Q2 2022.
Paul Tudor Jones's largest addition to Keros Therapeutics, Inc. (KROS) was in Q3 2025, adding 19,525 shares worth $308,886.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 28,007 shares of Keros Therapeutics, Inc. (KROS), valued at approximately $309,197.
As of the Q1 2026 filing, Keros Therapeutics, Inc. (KROS) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Keros Therapeutics, Inc. (KROS) was 28,307 shares, as reported at the end of Q4 2025.